Join Us

Mission Statement Image

Media Room

New ASBM Survey Reveals Key Safety Concern Associated with Biosimilar Naming

Thursday, September 13th, 2012

The Alliance for Safe Biologics released a new survey examining physician practices and perspectives with regard to biosimilar medicine identification and substitution – policy issues that remain unresolved and will have a fundamental impact on patient safety. Over 350 endocrinologists, dermatologists, oncologists, rheumatologists, nephrologists and neurologists – all specialties that prescribe biologics – responded to the survey.

View the ASBM Biosimilars Survey.